Novel (p-Tolyl)-3(2H)-Pyridazinone Derivatives Containing Substituted-1,2,3-Triazole Moiety as New Anti-Alzheimer Agents: Synthesis, In vitro and In silico Assays; [1,2,3-Triazol Uygulaması Yeni Anti-Alzheimer (P-Tolil)-3(2H)-Piridazinon Türevleri: Sentez Çalışmaları, in vitro ve in siliko Analizleri]
Özet
Alzheimer’s disease (AD) is a chronic neurodegenerative disease that is the most common cause of dementia. The risk of developing the disease increases with age. When the histopathology of the disease is examined, senile amyloid plaques, neurofibrillary tangle formation, synapse-neuron loss, and marked atrophy in the brain are detected. The decrease in the level of choline acetyltransferase, which is responsible for the synthesis of acetylcholine in Alzheimer’s disease, is 58-90%. There is a great need for new drugs that target the basis of the cause of the disease, as existing drugs cannot stop the progression of the disease. In this study, triazole-pyridazinone derivative compounds showing acetylcholinesterase inhibition were synthesized and their inhibitions were investigated. Compound 6e exhibited the strongest inhibitory effect with a Ki value of 0.049 ± 0.014 µM (Tacrine Ki= 0.226 ± 0.025 µM). In addition, in silico studies were applied for all compounds. © 2022 Society of Pharmaceutical Sciences of Ankara (FABAD). All rights reserved.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Bozbey Merde, İrem | |
| dc.contributor.author | Taşkor Önel, Gülce | |
| dc.contributor.author | Türkmenoğlu, Burçin | |
| dc.contributor.author | Gürsoy, Şule | |
| dc.contributor.author | Di̇Lek, Esra | |
| dc.date.accessioned | 2026-10-18T20:27:26.778532397Z | |
| dc.date.available | 2026-10-18T20:27:26.778532397Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | Alzheimer’s disease (AD) is a chronic neurodegenerative disease that is the most common cause of dementia. The risk of developing the disease increases with age. When the histopathology of the disease is examined, senile amyloid plaques, neurofibrillary tangle formation, synapse-neuron loss, and marked atrophy in the brain are detected. The decrease in the level of choline acetyltransferase, which is responsible for the synthesis of acetylcholine in Alzheimer’s disease, is 58-90%. There is a great need for new drugs that target the basis of the cause of the disease, as existing drugs cannot stop the progression of the disease. In this study, triazole-pyridazinone derivative compounds showing acetylcholinesterase inhibition were synthesized and their inhibitions were investigated. Compound 6e exhibited the strongest inhibitory effect with a Ki value of 0.049 ± 0.014 µM (Tacrine Ki= 0.226 ± 0.025 µM). In addition, in silico studies were applied for all compounds. © 2022 Society of Pharmaceutical Sciences of Ankara (FABAD). All rights reserved. | |
| dc.description.sponsorship | The authors would like to thank Erzincan Binali Yıldırım University, Basic Sciences Application and Research Center (EBYU-EUTAM) for the Schrödinger Maestro 2021-2 program. | |
| dc.identifier.doi | 10.55262/fabadeczacilik.1128446 | |
| dc.identifier.eissn | 2651-4648 | |
| dc.identifier.endpage | 368 | |
| dc.identifier.issn | 1300-4182 | |
| dc.identifier.issue | 3 | |
| dc.identifier.scopus | 2-s2.0-85160877335 | |
| dc.identifier.startpage | 355 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/12555 | |
| dc.identifier.volume | 47 | |
| dc.language.iso | en | |
| dc.publisher | Society of Pharmaceutical Sciences of Ankara (FABAD) | |
| dc.relation.ispartof | Fabad Journal of Pharmaceutical Sciences | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | 3(2H)-pyridazinone | |
| dc.subject | acetylcholinesterase | |
| dc.subject | molecular docking | |
| dc.subject | (para tolyl) 3(2h) pyridazinone derivative | |
| dc.subject | 2 [2 (4 phenyl 5 thioxo 4,5 dihydro 1h 1,2,4 triazol 3 yl)ethyl] 6 (para tolyl)pyridazin 3(2h) one | |
| dc.subject | 2 [2 [4 (2 methoxyphenyl) 5 thioxo 4,5 dihydro 1h 1,2,4 triazol 3 yl)ethyl] 6 (para tolyl)pyridazin 3(2h) one | |
| dc.subject | 2 [2 [4 (4 bromophenyl) 5 thioxo 4,5 dihydro 1h 1,2,4 triazol 3 yl)ethyl] 6 (para tolyl)pyridazin 3(2h) one | |
| dc.subject | 2 [2 [5 thioxo 4 (para tolyl) 4,5 dihydro 1h 1,2,4 triazol 3 yl] ethyl] 6 (para tolyl)pyridazin 3(2h) one | |
| dc.subject | 2 [2 [5 thioxo 4 [4 (trifluoromethoxy)phenyl] 4,5 dihydro 1h 1,2,4 triazol 3 yl]ethyl 6 (para tolyl)pyridazin 3 (2h) one | |
| dc.subject | cholinesterase inhibitor | |
| dc.subject | nootropic agent | |
| dc.subject | pyridazinone derivative | |
| dc.subject | tacrine | |
| dc.subject | unclassified drug | |
| dc.subject | Alzheimer disease | |
| dc.subject | Article | |
| dc.subject | carbon nuclear magnetic resonance | |
| dc.subject | cholinesterase inhibition | |
| dc.subject | computer model | |
| dc.subject | controlled study | |
| dc.subject | crystal structure | |
| dc.subject | drug synthesis | |
| dc.subject | enzyme inhibition | |
| dc.subject | gene expression | |
| dc.subject | IC50 | |
| dc.subject | in vitro study | |
| dc.subject | protein expression | |
| dc.subject | proton nuclear magnetic resonance | |
| dc.subject | room temperature | |
| dc.subject | structure activity relation | |
| dc.title | Novel (p-Tolyl)-3(2H)-Pyridazinone Derivatives Containing Substituted-1,2,3-Triazole Moiety as New Anti-Alzheimer Agents: Synthesis, In vitro and In silico Assays; [1,2,3-Triazol Uygulaması Yeni Anti-Alzheimer (P-Tolil)-3(2H)-Piridazinon Türevleri: Sentez Çalışmaları, in vitro ve in siliko Analizleri] | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 13 | |
| rdl.citation.trdizin | 0 | |
| rdl.department | ERZİNCAN BİNALİ YILDIRIM ÜNİVERSİTESİ | |
| rdl.oa.status | green | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | TRDIZIN |
